Entry |
|
Name |
Olmesartan medoxomil and azelnidipine; Rezaltas (TN) |
Component |
|
Class |
Cardiovascular agent
DG01925 Renin-angiotensin system inhibitor
DG03231 Antihypertensive
Metabolizing enzyme substrate
DG01633 CYP3A/CYP3A4 substrate
DG02913 CYP3A4 substrate
|
Remark |
Therapeutic category: | 2149 |
|
Efficacy |
Antihypertensive |
Comment |
Azelnidipine is primarily metabolized by CYP3A4.
|
Metabolism |
Enzyme: CYP3A4 [HSA: 1576]
|
Interaction |
|
Brite |
Therapeutic category of drugs in Japan [BR:br08301]
2 Agents affecting individual organs
21 Cardiovascular agents
214 Antihypertensives
2149 Others
D09594 Olmesartan medoxomil and azelnidipine
Drug groups [BR:br08330]
Cardiovascular agent
DG01925 Renin-angiotensin system inhibitor
D09594 Olmesartan medoxomil and azelnidipine
DG03231 Antihypertensive
D09594 Olmesartan medoxomil and azelnidipine
Metabolizing enzyme substrate
DG01633 CYP3A/CYP3A4 substrate
DG02913 CYP3A4 substrate
D09594 Olmesartan medoxomil and azelnidipine
Drug classes [BR:br08332]
Cardiovascular agent
DG03231 Antihypertensive
D09594 Olmesartan medoxomil and azelnidipine
Drug metabolizing enzymes and transporters [br08309.html]
Drug metabolizing enzymes
D09594
|
Other DBs |
|
LinkDB |
|